EP1663221A4 - Compositions ophtalmiques pour traiter l'hypertension oculaire - Google Patents

Compositions ophtalmiques pour traiter l'hypertension oculaire

Info

Publication number
EP1663221A4
EP1663221A4 EP04782774A EP04782774A EP1663221A4 EP 1663221 A4 EP1663221 A4 EP 1663221A4 EP 04782774 A EP04782774 A EP 04782774A EP 04782774 A EP04782774 A EP 04782774A EP 1663221 A4 EP1663221 A4 EP 1663221A4
Authority
EP
European Patent Office
Prior art keywords
ocular hypertension
ophthalmic compositions
treating ocular
treating
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04782774A
Other languages
German (de)
English (en)
Other versions
EP1663221A1 (fr
Inventor
Meng Hsin Chen
James B Doherty
Luping Liu
Swaminathan Natarajan
Robert M Tynebor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1663221A1 publication Critical patent/EP1663221A1/fr
Publication of EP1663221A4 publication Critical patent/EP1663221A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP04782774A 2003-09-04 2004-08-31 Compositions ophtalmiques pour traiter l'hypertension oculaire Withdrawn EP1663221A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50009003P 2003-09-04 2003-09-04
PCT/US2004/028351 WO2005025568A1 (fr) 2003-09-04 2004-08-31 Compositions ophtalmiques pour traiter l'hypertension oculaire

Publications (2)

Publication Number Publication Date
EP1663221A1 EP1663221A1 (fr) 2006-06-07
EP1663221A4 true EP1663221A4 (fr) 2009-04-22

Family

ID=34312180

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04782774A Withdrawn EP1663221A4 (fr) 2003-09-04 2004-08-31 Compositions ophtalmiques pour traiter l'hypertension oculaire

Country Status (7)

Country Link
US (1) US7494983B2 (fr)
EP (1) EP1663221A4 (fr)
JP (1) JP2007504236A (fr)
CN (1) CN1842335A (fr)
AU (1) AU2004271978B2 (fr)
CA (1) CA2537430A1 (fr)
WO (1) WO2005025568A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043354A2 (fr) * 2002-11-08 2004-05-27 Merck & Co., Inc. Compositions ophtalmiques pour traiter l'hypertension oculaire
AU2004272546B2 (en) * 2003-09-04 2007-10-18 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
AU3693789A (en) 1988-05-10 1989-11-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) New ophthalmic preparation for treating glaucoma
ATE101342T1 (de) 1988-09-06 1994-02-15 Kabi Pharmacia Ab Prostaglandinderivate zur behandlung des gruenen stars oder einer okularen hypertension.
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
CA2164733A1 (fr) 1993-06-08 1994-12-22 Nino Sorgente Methodes et compositions pour abaisser la pression intraoculaire
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5573758A (en) 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US5925342A (en) 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
KR20010074981A (ko) 1998-09-14 2001-08-09 우에노 도시오 ω치환된 페닐프로스타그란딘 Ｅ 유도체 및 그 유도체를유효 성분으로 하는 약제
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GEP20043203B (en) 1999-12-22 2004-03-25 Pfizer Prod Inc EP4 Receptor Selective Agonists in the Treatment of Osteoporosis
EP1268439A1 (fr) * 2000-03-17 2003-01-02 Alcon Inc. Derives d'indazole 5-hydroxy permettant de traiter le glaucome
CA2402403A1 (fr) 2000-03-17 2001-09-27 Alcon, Inc. Derives de 6-hydroxy-indazole destines au traitement du glaucome
AU4466901A (en) 2000-03-31 2001-10-08 Toray Industries, Inc. Hair growth or hair formation controlling agents
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
NZ525164A (en) 2000-11-27 2005-04-29 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
ATE318821T1 (de) * 2001-06-01 2006-03-15 Alcon Inc Pyranoindazole und ihre verwendung in der glaukombehandlung
WO2004043354A2 (fr) * 2002-11-08 2004-05-27 Merck & Co., Inc. Compositions ophtalmiques pour traiter l'hypertension oculaire
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
EP1479675A1 (fr) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Derivés d'indazole en tant qu'inhibiteurs du facteur Xa

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
AU2004271978B2 (en) 2009-02-05
US20070027188A1 (en) 2007-02-01
AU2004271978A1 (en) 2005-03-24
EP1663221A1 (fr) 2006-06-07
JP2007504236A (ja) 2007-03-01
CA2537430A1 (fr) 2005-03-24
CN1842335A (zh) 2006-10-04
US7494983B2 (en) 2009-02-24
WO2005025568A1 (fr) 2005-03-24

Similar Documents

Publication Publication Date Title
EP1646614A4 (fr) Compositions ophtalmiques destinees au traitement d'hypertension oculaire
EP1666027A4 (fr) Composition ophtalmique pour lentille de contact
EP1581503A4 (fr) Compositions ophtalmiques pour traiter l'hypertension oculaire
EP1664011A4 (fr) Compositions ophtalmiques pour le traitement de l'hypertension oculaire
EP1515722A4 (fr) Compositions ophtalmiques destinees a traiter l'hypertension oculaire
BRPI0317545A2 (pt) "composições de poli-hema de baixa polidispersão"
AU2002305278A1 (en) Bifurcatable trabecular shunt for glaucoma treatment
IS7215A (is) Aðferðir til að meðhöndla nýæðarsjúkdóma í augum
DZ3347A1 (fr) Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase
EP1583750A4 (fr) Inhibiteurs de beta-secretase macrocyclique pour traiter la maladie d'alzheimer
EP1534074A4 (fr) Polytherapie pour le traitement de l'obesite
GB2402674B (en) Compositions and methods for the treatment of glaucoma or ocular hypertension
PL377172A1 (pl) Kompozycje do oczu do leczenia nadciśnienia śródgałkowego
FR2860654B1 (fr) Bougie d'allumage pour temperatures elevees
EP1515721A4 (fr) Compositions ophthalmiques pour traiter l'hypertension oculaire
FR2879914B1 (fr) Ecarteur-retenteur d'intestins pour chirurgie coelioscopique
FR2860427B1 (fr) Insert humeral pour une prothese d'epaule inversee.
EP1771170A4 (fr) Compositions ophtalmiques traitant l'hypertension oculaire
EP1558238A4 (fr) Beta-hydroxyphenylaldylamines et utilisation de celles-ci pour traiter le glaucome
EP1663221A4 (fr) Compositions ophtalmiques pour traiter l'hypertension oculaire
EP1660685A4 (fr) Inhibition antisens de l expression de lamininine-8 pour l'inhibition de gliomes humain
EP1802300A4 (fr) Compositions ophtalmiques servant a traiter l'hypertension oculaire
EP1610776A4 (fr) Compositions ophtalmiques pour traiter une hypertension oculaire
ZA200302911B (en) Method and composition for treatment of ocular hypertension and glaucoma.
EP1410795A4 (fr) Remedes pour maladies oculaires allergiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060404

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT LV

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20060404

Extension state: LT

Payment date: 20060404

A4 Supplementary search report drawn up and despatched

Effective date: 20090324

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20100112